

DMB

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

Display Date	10-1-98
Publication Date	10-2
Certifier	<i>[Signature]</i>

**Food and Drug Administration**

**Obstetrics and Gynecology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting**

**AGENCY:** Food and Drug Administration, HHS

**ACTION:** Notice.

---

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

*Name of the Committee:* Obstetrics and Gynecology Devices Panel of the Medical Devices Advisory Committee.

*General Function of the Committee:* To provide advice and recommendations to the agency on FDA's regulatory issues.

*Date and Time:* The meeting will be held on October 19, 1998, 10 a.m. to 6 p.m., and October 20, 1998, 8:30 a.m. to 5 p.m.

*Location:* Parklawn Bldg., conference rooms G and H, 5600 Fishers Lane, Rockville, MD.

*Contact Person:* Elisa D. Harvey, Center for Devices and Radiological Health (HFZ-470), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-1180 or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12524. Please call the Information Line for up-to-date information on this meeting.

*Agenda:* On October 19, 1998, the committee will discuss, make recommendations, and vote on a premarket approval application for a thermal endometrial ablation system intended to treat women with abnormal uterine bleeding. On October 20, 1998, in the context of the current guidance document on thermal endometrial ablation devices entitled "Thermal Endometrial Ablation Devices," the committee will discuss: (1) Initial safety studies, as well as the pivotal safety and

NM 1

effectiveness study, for postmenopausal patients on hormone replacement therapy, which will include inclusion/exclusion criteria, type(s) of control, and length of followup, both premarket and postmarket; and (2) proposed labeling for vacuum-assisted delivery devices. Single copies of the guidance document are available to the public by contacting the Division of Small Manufacturers Assistance, Center for Devices and Radiological Health, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 1-800-638-2041 or 301-443-6597 or by faxing your request to 301-443-8818 and requesting the document by shelf No. 547.


*Procedure:* On October 19, 1998, from 10:45 a.m. to 6 p.m. and on October 20, 1998, from 8:30 a.m. to 5 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by October 14, 1998. Oral presentations from the public will be scheduled between approximately 11 a.m. and 11:30 a.m. on October 19, 1998. Near the end of the committee deliberations on October 19, 1998, a 30-minute open public session will be conducted for interested persons to address issues specific to the submission before the committee. Oral presentations from the public will be scheduled between approximately 8:45 a.m. and 9:15 a.m. and between approximately 1:15 p.m. and 1:45 p.m. on October 20, 1998. Time allotted for each presentation may be limited. Those desiring to make formal presentations should notify the contact person before October 14, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and address of proposed participants, and an indication of the approximate time requested to make their presentation.

*Closed Committee Deliberations:* On October 19, 1998, from 10 a.m. to 10:45 a.m., the meeting will be closed to the public to permit FDA to present to the committee trade secret and/or confidential commercial information (5 U.S.C. 552b(c)(4)) regarding pending issues.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.

2).

Dated: September 24, 1998




Michael A. Friedman  
Deputy Commissioner for Operations

[FR Doc. 98-???? Filed ??-??-98; 8:45 am]

**BILLING CODE 4160-01-F**

**CERTIFIED TO BE A TRUE COPY OF THE ORIGINAL**



# **Thermal Endometrial Ablation Devices**

## **SUBMISSION GUIDANCE FOR AN IDE**

**FINAL: March 14, 1996**

Developed by:

Obstetrics and Gynecology Devices Branch  
Office of Device Evaluation, HFZ-470  
9200 Corporate Blvd  
Rockville, MD 20850  
(301) 594-1180

# Table of Contents

Introduction .....	1
Device Design and Description .....	1
Device Description .....	1
Materials .....	1
Biocompatibility Testing .....	2
Software .....	2
Device Performance .....	3
Design Specifications .....	3
Electrical Safety .....	3
Electromagnetic Compatibility .....	3
Labeling .....	3
Manufacturing .....	4
Sterilization .....	4
Reusable components .....	4
Single-use components .....	5
Other required information .....	6
Commercialization .....	6
Environmental Impact .....	6
Summary of all prior investigations .....	6
In vitro and animal testing .....	6
Clinical Testing .....	6
Feasibility Study - Safety .....	7
Objectives .....	7
Description of patient population .....	7
Investigational Plan .....	7
Risk Analysis .....	8
Informed Consent .....	8
Feasibility Study - Effectiveness .....	8
Objectives .....	8
Description of patient population .....	9
Investigational Plan .....	10
Risk Analysis .....	11
Informed Consent .....	11

Safety and Effectiveness Study .....	11
Objectives .....	11
Description of patient population .....	11
Investigational Plan .....	12
Follow-up .....	14
Risk Analysis .....	14
Data Analysis .....	14
Related FDA Documents .....	16
References .....	17

## I. Introduction

This guidance is intended to identify the elements that the Office of Device Evaluation (ODE) would expect to see in an Investigational Devices Exemptions (IDE) application for a Thermal Endometrial Ablation Device. This group of devices includes new types of devices that are intended to ablate the endometrium using conductive heating, RF energy, microwave energy, cryosurgery, etc., and where the user has no direct control over the course of the procedure once it has begun (i.e., no feedback). It is important to understand that certain technologies may not require all of the information contained herein, whereas other technologies may require additional studies beyond the scope of this guidance document.

For general information about how to submit an IDE application, contact the Center for Devices and Radiological Health's (CDRH) Division of Small Manufacturers Assistance (DSMA) at (800) 638-2041 or (301) 443-6597. FDA welcomes comments on this draft guidance document and will consider all scientifically valid alternatives to the preclinical and clinical requirements stated within. *It is also highly recommended that the sponsor of a new investigation contact the Obstetrics and Gynecology Devices Branch (OGDB) within the Office of Device Evaluation (ODE) prior to submission of an original IDE application, at (301) 594-1180.*

## II. Device Design and Description

### A. Device Description

A thorough understanding of device design is essential not only in evaluating the functional characteristics of the device but also in evaluating the clinical application of the device. Provide a brief overview of the principles of operation of the device. This should include:

1. fully dimensioned engineering drawings
2. description of all user-accessible controls, including:
  - a. range of control settings
  - b. defaults (if any)
3. block diagram (including all temperature monitoring and feedback circuitry)
4. complete characterization of all components (e.g., for thermocouples provide operating range and sensitivity)
5. samples (where feasible) or a videotape showing the device in operation are helpful

### B. Materials

Provide a complete list of all patient-contacting materials, and where relevant, provide a discussion as to why a given material was chosen for a particular function. If any patient-contacting material contains a color pigment, please

provide the following information: chemical composition, color index number, and color additive listing (from 21 CFR 73).

C. Biocompatibility Testing (for patient-contacting devices)

Provide either biocompatibility testing (performed on the finished device), or certification that identical materials are used in a legally marketed device with a similar intended use. Samples for biocompatibility testing should be prepared in such a way so as to reflect the actual conditions of use (e.g., if the material will be heated to 90°C during use, it should be heated to this temperature prior to testing). Tests should be conducted in conformance with Good Laboratory Practices (GLP) in accordance with 21 CFR 58.

For additional information on biocompatibility, please refer to the Blue Book Memorandum "Use of International Standard ISO-10993, 'Biological Evaluation of Medical Devices Part 1: Evaluation and Testing'", available from DSMA.

D. Software

Please provide documentation describing the software development lifecycle and risk management activities. This should include:

1. A description of the software development activities and software quality assurance procedures over the software life cycle.
2. System and software requirements and design. This should include: hardware requirements, programming language and program size, and software functional requirements. Traceability between safety requirements and hazards should be clearly indicated.
3. A structure chart depicting the partition of the system into functional units.
4. A description of the verification and validation activities at unit, integration, and system level, including pass/fail criteria, and the system level functional test plan. Traceability between hazards, safety functions, and testing should be demonstrated.
5. A summary of the verification and validation test results *in sufficient detail to demonstrate that software requirements were met* at various levels of testing, and the results of system level testing.
6. Current software version number and date, as well as a list of any remaining bugs or errors.



Additional guidance on software documentation can be found in "Reviewer Guidance for Computer Controlled Medical Devices Undergoing 510(k) Review", available from DSMA.

### **III. Device Performance**

#### **A. Design Specifications**

1. Provide a rationale for all important specifications. For example, if it is specified that the catheter must be able to withstand a tensile force of 5 lbf, please provide a justification for why 5 lbf is appropriate.
2. System-level hazard analysis . Identify each potential hazardous event, the level of concern, the method of control for this event, the corrective measures taken, and the testing and evaluation done to show that the corrective measures are effective.

#### **B. Electrical Safety** Provide either:

1. Certification that the device complies with applicable electrical safety standards (e.g., IEC 601-1, UL 544, UL 2601); or
2. Test results which guarantee a similar level of protection.

#### **C. Electromagnetic Compatibility (EMC)** Provide either:

1. Certification that the device complies with applicable EMC standards (e.g., IEC 601-1-2, IEC 801-2,3,4,5, CISPR 11); or
2. Test results which guarantee a similar level of protection; or
3. Justification for why this information is unnecessary (e.g., due to device design or working conditions).

#### **D. System-level Testing** Provide system-level testing demonstrating that the device performs as designed (e.g., it heats to the desired temperature, thermocouples accurately record temperature, etc.). Include:

1. test protocol and methods
2. results (including samples of raw data)
3. conclusions

### **IV. Labeling**

Provide samples of all device labeling. The labeling must include the following information (21 CFR 812.5):

- A. name and place of business of the manufacturer, packer, or distributor
- B. quantity of contents (if appropriate)
- C. directions for use
- D. reprocessing instructions (see Section VI).
- E. description of all relevant contraindications, hazards, adverse effects, interfering substances or devices, warnings, and precautions
- F. the statement: "CAUTION - Investigational Device, Limited by Federal law to investigational use."

**Note:** 21 CFR 812.5 (b) stipulates that the labeling of an investigational device shall not bear any statement that is false or misleading in any particular and shall not represent that the device is safe or effective for the purposes for which it is being investigated.

## **V. Manufacturing**

Provide a description of the methods, facilities, and controls used for the manufacture, processing, packaging, and storage of the device, in sufficient detail so that a person generally familiar with Good Manufacturing Practices can make a knowledgeable judgement about the quality control used in the manufacture of the device.

## **VI. Sterilization**

Devices that are intended to contact or enter sterile tissue or a normally sterile body cavity, such as the uterus, require sterilization before use.

### **A. Reusable components**

Provide detailed instructions for reprocessing (cleaning and sterilizing) the device, including instructions necessary for any assembly/disassembly. Also, include a warning that the device should be thoroughly cleaned and sterilized according to validated infection control procedures before use/reuse.

1. The cleaning instructions should describe careful, manual cleaning and rinsing of both the device's exterior surface and any interior channels using a brush and detergent/ enzymatic solution to dissolve and loosen proteinaceous materials immediately after use. The cleaning instructions should identify compatible cleaning solutions by generic names (e.g., enzymatic cleaning solutions, protein binding agents, etc.) and any areas of the device that are particularly difficult to clean, as well as any specified methods and necessary accessories (e.g., brushes).

2. The rinsing instructions should include purging of all internal channels (if applicable) alternately with air and water.
3. Any liquid sterilants used must be identified and cleared by FDA. General reference to a class of germicides, e.g., 2% glutaraldehyde, is currently acceptable. Instructions should recommend that the entire device be exposed to the liquid chemical germicide according to the labeling of the germicide (appropriate time and temperature). Liquid sterilization may be manual or automated, and, if automated, instructions must identify suitable adapters for all interior channels.
4. Thorough post process drying instructions should be recommended, as needed, in order to reduce recontamination before reuse. Instructions should include a step where air is forced through all channels following either manual or automated reprocessing to remove residual rinse water.
5. Specify at least one validated method for sterilization and identify the specific parameters (e.g., cycle parameters, aeration, specific liquid chemical germicide, loading of sterilizer, etc.) which should be used. If the labeling lists a generic type of sterilization process with no specifics on cycle parameters, then the applicant must validate all forms of the listed generic process, e.g., "steam sterilization."
6. Provide information to help the user identify any circumstances or conditions when the device may be adversely affected by reprocessing. This information should address the material compatibility with the immersion fluid.
7. Provide a certification regarding validation of the reprocessing instructions signed by the applicant, its agent, or other legally responsible individual.

For important additional information on reprocessing, please refer to the draft "Labeling Reusable Medical Devices Reprocessing in Health Care Facilities: FDA Reviewer Guidance" (March 1995). A copy of this guidance may be obtained from DSMA.

B. Single-use components

1. Provide the method of sterilization, and the sterility assurance level.
2. Identify the method used to validate the sterilization procedures. If the method is a standard, well-recognized method, simply provide the name. If not, please provide a copy of the protocol itself.
3. Describe the packaging system that will maintain sterility.

4. If the device is sterilized using ethylene oxide, identify the maximum levels of residues of ethylene oxide, ethylene chlorohydrin and ethylene glycol. If the device is radiation sterilized, identify the radiation dose.

## **VII. Other required information (812.20)**

- A. Commercialization.  
Specify whether or not the device is to be sold to the patient during the clinical study. If so, explain why this does not constitute commercialization.
- B. Environmental Impact.  
Provide either:
  1. An environmental impact assessment describing the potential environmental impact of manufacturing and investigating the device, OR
  2. A claim for categorical exclusion from the requirement, in accordance with 21 CFR 25.24.

## **VIII. Summary of all prior investigations**

- A. In vitro and animal testing  
Provide a complete description of all in vitro (e.g., extirpated uteri) and animal testing. This should include:

1. justification for choice of model
2. comparison of the treatment parameters used in the study to those proposed to be used in humans
3. test protocols and methods
4. results (including samples of raw data)
5. conclusions

**Note:** Adequate data from in vitro and animal testing, demonstrating that the device is relatively safe and that it functions as intended, must be submitted before approval for clinical studies in humans will be granted.

- B. Clinical Testing  
Provide the following information about all prior clinical investigations involving the device:

1. complete bibliography, including copies of important references
2. summary of unpublished data
3. complete discussion of all known adverse events or device failures

## **IX. Feasibility Study - Safety (Pre-hysterectomy patients)**

### **A. Objectives**

The purpose of the Feasibility Safety Study is to demonstrate the safety of the device in a limited number of women already scheduled for a hysterectomy. This involves monitoring temperatures within the uterine wall and on the serosal surface during the ablation procedure, and conducting a histological examination of the uterus once it is removed.

Significant changes to the temperature/time parameters or to the system design may require revalidation via an additional feasibility study.

### **B. Description of patient population**

#### **1. Inclusion criteria**

- a. patients diagnosed as suitable candidates for a hysterectomy
- b. uterine sound measurement  $\leq 8$  cm
- c. other device specific criteria

**Note:** If the safety and effectiveness study will include women who have had previous uterine surgery (e.g., caesarean section, myomectomy), then the safety study should include sufficient numbers of both women who have had previous uterine surgery and those who have not.

#### **2. Exclusion criteria**

- a. active pelvic inflammatory disease
- b. abnormal psp smear, unless appropriately evaluated
- c. history of gynecologic malignancy within the past 5 years
- d. submucous myomas and polyps
- e. septate uterus
- f. previous endometrial ablation procedure
- g. pregnancy
- h. other device specific criteria

### **C. Investigational Plan**

#### **1. Study Design**

This is a single-arm study with 5-10 patients.

#### **2. Protocol**

a. Pre-procedure evaluation should include:

- (1) pelvic examination
- (2) Pap smear
- (3) pregnancy test
- (4) endometrial biopsy

b. Endometrial preparation

All patients should receive either hormonal pre-treatment to thin the endometrium, or an immediate pre-procedure D&C. All subjects should receive the same pre-treatment regimen.

c. Endometrial ablation protocol

- (1) Provide the procedures used for the ablation procedure. Ablation parameters should be exactly the same as those to be used in the safety and effectiveness study. If they are not, provide a detailed discussion of why results from the feasibility study will still be relevant.
- (2) The following data should be collected:
  - (a) temperature measurements during the ablation procedure, including the location of the thermocouples or other temperature measuring devices.
  - (b) histology, including both gross and microscopic.
  - (c) depth of penetration of thermal injury.
- (3) Provide a complete discussion of any adverse events.

3. Follow-up

Patients should be followed-up according to the standard of care for hysterectomy.

D. Risk Analysis

Provide a complete description of all potential risks to the patient.

E. Informed Consent

Provide copies of the informed consent forms that will be used during the study. You may wish to consult the "Investigational Device Exemption Manual", available from DSMA, for additional guidance on informed consent.

**X. Feasibility Study - Effectiveness**

A. Objectives

The purpose of this study is to establish tentative effectiveness rates for use in sample size calculations, and to support beginning a full-scale safety and effectiveness study. This is a single arm feasibility study in at least 20 women who are candidates for endometrial ablation.

Note: Previously collected data from studies conducted at foreign sites may be accepted in lieu of this study. In this case, the following information should be provided:

1. Summary of study design
    - a. inclusion/exclusion criteria
    - b. detailed description of procedure - should be exactly the same as what will be proposed in proposed pivotal study (Section XI)
    - c. follow-up procedures
  2. Summary of safety and effectiveness data
    - a. sufficient number of patients
    - b. low adverse event rate
    - c. reasonable effectiveness rate
- B. Description of patient population
1. Inclusion criteria
    - a. uterine bleeding resulting from a benign condition that meets the study entrance requirements for excessive uterine bleeding. (Note: the study sponsor is responsible for determining and justifying what constitutes excessive uterine bleeding).
    - b. uterine sound measurements  $\leq 12$  cm
    - c. other device-specific criteria
  2. Exclusion criteria
    - a. active pelvic inflammatory disease
    - b. clotting defects or bleeding disorders
    - c. abnormal Pap smear, unless appropriately evaluated
    - d. malignant pathology, as documented by endometrial biopsy
    - e. history of gynecologic malignancy within the past 5 years
    - f. submucous myomas and polyps
    - g. septate uterus
    - h. previous endometrial ablation procedure
    - i. previous uterine surgeries, unless these patients have previously been included in the safety study
    - j. pregnancy
    - k. desire for future fertility
    - l. other device-specific criteria

C. Investigational Plan

1. Study Design

a. Hypothesis

The study sponsor must determine the appropriate hypothesis and study endpoints. Primary study endpoints should be quantitative in nature (e.g., reduction in uterine bleeding, elimination of uterine bleeding (amenorrhea), increase in hematocrit). However, studies should also include a secondary quality-of-life endpoint.

b. Follow-up

Six months of follow-up data from this "Feasibility - Effectiveness" study should be provided to FDA prior to submission of an IDE for the safety and efficacy study. *In addition, all patients should be followed for a total of 2 years (i.e., 6 months pre-submission plus 18 months post-submission). Once all data are collected, a final report should be submitted to FDA.*

2. Protocol

a. Pre-procedure examination

- (a) pelvic examination
- (b) Pap smear
- (c) pregnancy test
- (d) hematocrit
- (e) diagnostic hysteroscopy with endometrial biopsy

b. Collection of baseline data

If patient blood loss is to be used as a study endpoint, baseline data should be collected for three months prior to the ablation procedure.

c. Endometrial preparation

Patients should receive either hormonal pre-treatment to thin the endometrium, or an immediate pre-procedure D&C. All subjects should receive the same pre-treatment regimen.

d. Endometrial ablation

Provide the following information for each patient:

- (1) The procedures used for the ablation procedure. Ablation parameters should be exactly the same as those to be used in the safety and effectiveness study. If they are not, provide a detailed discussion of why the results will still be relevant.
- (2) Adverse events



3. Follow-up  
Patients should receive follow-up examinations at the following intervals:  
2 weeks, 3 months, and 6 months. The study sponsor should account for  
all patients lost to follow-up.

D. Risk Analysis  
Provide a complete description of all risks to the patient.

E. Informed Consent  
Provide copies of the informed consent forms that will be used during the study.  
You may wish to consult the "Investigational Device Exemption Manual",  
available from DSMA, for additional guidance on informed consent.

## XI. Safety and Effectiveness Study

A. Objectives  
The purpose of this study is to obtain the safety and effectiveness data necessary  
to support a PMA.

B. Description of patient population

### 1. Inclusion criteria

- a. uterine bleeding resulting from a benign condition that meets the  
study entrance requirements for excessive uterine bleeding, and  
which continues for multiple cycles. (Note: the study sponsor is  
responsible for determining and justifying what constitutes  
excessive uterine bleeding. The ACOG guidelines for endometrial  
ablation offer one possible alternative.)
- b. previously failed medical therapy with either oral contraceptives or  
cyclic progestins. Patients who were previously unsuccessfully  
treated with medical therapy must provide records documenting the  
previous treatment.  
*Note: This inclusion criterion is intended to exclude anovulatory  
patients from the study, so as to produce a "cleaner" study. It is  
not intended to reflect the ultimate use of the device once it has  
been cleared by FDA.*
- c. uterine sound measurements  $\leq 12$  cm
- d. other device specific criteria

### 2. Exclusion criteria

- a. active pelvic inflammatory disease
- b. clotting defects or bleeding disorders
- c. abnormal Pap smear, unless appropriately evaluated
- d. malignant pathology, as documented by endometrial biopsy
- e. history of gynecologic malignancy within the past 5 years
- f. submucous myomas and polyps
- g. intramural fibroids
- h. septate uterus
- i. previous endometrial ablation procedure
- j. previous uterine surgeries, unless these patients have previously been included in the safety study
- k. pregnancy
- l. desire for future fertility
- m. other device-specific criteria

### C. Investigational Plan

#### 1. Study Design

##### a. Prospective, Randomized, Controlled

- (1) The study should compare the investigational device to a legally marketed device intended for endometrial ablation (e.g., electrosurgical resection, rollerball ablation, or laser ablation). Control arms such as sham or D&C are not acceptable.
- (2) Describe the methods used to ensure uniformity of the control procedure from investigator to investigator. A single control procedure should be chosen, and investigators must be of recognized competence in performing the procedure.
- (3) Multi-Center  
The study should be conducted at several centers, with at least 10 patients from each procedure at each center.
- (4) Describe the methods that will be used to minimize bias, including:
  - (a) randomization of patient selection process
  - (b) procedures intended to prevent "shopping" for treatment

##### b. Hypothesis

The study sponsor must determine the appropriate hypothesis and study endpoints. Primary study endpoints should be quantitative in nature (e.g., reduction in uterine bleeding, elimination of uterine bleeding (amenorrhea), increase in hematocrit). However, studies should also include a secondary quality-of-life endpoint, based on a scaled questionnaire. In addition, the sponsor should also collect data on the amenorrhea rate and the need for future surgical interventions.

- c. Number of study subjects
  - (1) provide appropriate statistical justification
  - (2) adequate numbers at each site - see C.1.a (2) above.
- d. Follow-up

12 months of follow-up data will be required prior to PMA approval. However, the PMA may be submitted once 6 months of data has been obtained for all subjects. *In addition, all patients should be followed for a total of 3 years (i.e., 1 year pre-approval plus 2 years in a post-market setting). Data collection in the post-approval setting should focus on the need for repeat ablations or hysterectomy - qualitative blood loss data need not be collected. Once all data are collected, a final report should be submitted to FDA as a PMA supplement.*

## 2. Protocol

- a. Pre-procedure examination should include:
  - (1) pelvic examination
  - (2) pap smear
  - (3) pregnancy test
  - (4) hematocrit
  - (5) endometrial biopsy
  - (6) uterine evaluation by one of the following: diagnostic hysteroscopy, transvaginal ultrasound, or hysterosalpingogram (HSG)
- b. Collection of baseline data

If patient blood loss is to be used as a study endpoint, baseline data should be collected for three months prior to the ablation procedure.
- c. Endometrial preparation

Patients in both study arms should receive either hormonal pre-treatment to thin the endometrium, or an immediate pre-procedure D&C. All subjects should receive the same pre-treatment regimen.

3. Follow-up

Patients should receive follow-up examinations at the following intervals:

- a. 2 weeks
  - (1) pelvic exam
  - (2) adverse event report
- b. 3 months
  - (1) pelvic exam
  - (2) adverse event report
  - (3) hematocrit
  - (4) evaluation of diaries and Quality of Life
- c. 6 months
  - (1) pelvic exam
  - (2) adverse event report
  - (3) hematocrit
  - (4) evaluation of diaries and Quality of Life
- d. 12 months
  - (1) adverse event report
  - (2) evaluation of diaries and Quality of Life

D. Risk Analysis

Provide a complete description of all risks to the patient.

E. Informed Consent

Provide copies of the informed consent forms that will be used during the study. You may wish to consult the "Investigational Device Exemption Manual", available from DSMA, for additional guidance on informed consent.

F. Data Analysis

The following analyses should be included as part of the PMA.

- 1. Patient tree showing the number of patients enrolled, the number of patients treated in each study arm, and the number of patients evaluated at each of the specified follow-up intervals.

2. Data table for each treated subject. Both a paper copy and a PC-formatted computer disk (Excel, Quattro Pro or Lotus 1-2-3) should be provided. The following information should be included in the table:
  - a. patient identifier
  - b. age
  - c. treatment site
  - d. control or test
  - e. treatment date
  - f. deviations from protocol? If so, describe elsewhere.
  - g. adverse events? If so, describe elsewhere.
  - h. pre-treatment blood loss value (or other primary endpoint)
  - i. 6-month blood loss value (or other primary endpoint)
  - j. 12-month blood loss value (or other primary endpoint)
  - k. pre-treatment quality of life
  - l. quality of life at 6 months
  - m. quality of life at 12 months
  - n. pre-treatment hematocrit
  - o. 6-month hematocrit
  - p. 12-month hematocrit
  - q. additional surgical intervention required?
  - r. treatment considered success at 6 months? (Y/N)
  - s. treatment considered success at 12 months? (Y/N)
3. Sample raw data (e.g., menstrual diaries)
4. Statistical analyses (as appropriate)

## **Related FDA Documents**

The following related documents are available from the Center for Devices and Radiological Health's (CDRH) Division of Small Manufacturers Assistance (DSMA) at (800) 638-2041 or (301) 443-6597.

Blue Book Memorandum "Use of International Standard ISO-10993, 'Biological Evaluation of Medical Devices Part 1: Evaluation and Testing'"

Reviewer Guidance for Computer Controlled Medical Devices Undergoing 510(k) Review

Labeling Reusable Medical Devices Reprocessing in Health Care Facilities: FDA Reviewer Guidance (March 1995)

Investigational Device Exemption Manual

## References

- Brill, A.I. (1995) What is the role of hysteroscopy in the management of abnormal uterine bleeding? *Clinical Obstetrics and Gynecology*, 38(2), pp.319-345.
- Chimbira, T.H. & A.C. Turnbull (1980) Relation between measured menstrual blood loss and patient's subjective assessment of loss, duration of bleeding, number of sanitary towels used, uterine weight and endometrial surface area, *British Journal of Obstetrics and Gynaecology*, 87, pp.603-609.
- Copperman, A.B., DeCherney, A.H. & D.L. Olive (1993) A case of endometrial cancer following endometrial ablation for dysfunctional uterine bleeding, *Obstetrics and Gynecology*, 82, pp.640-642.
- DeCherney, A.H., Diamond, M.P., Lavy, G. & M.L. Polan (1987) Endometrial ablation for intractable uterine bleeding: hysteroscopic resection, *Obstetrics and Gynecology*, 70, pp.668-670.
- Deeny, M. and J.A. Davis (1994) Amount of menstrual blood loss in women referred for endometrial ablation, *European Journal of Obstetrics and Gynecology*, 57, pp.179-180.
- Eijkelen, M.A. et al (1986) The alkaline hematin method for measuring menstrual blood loss - a modification and its clinical use in menorrhagia, *European Journal of Obstetrics Gynecology and Reproductive Biology*, 22, pp.345-351.
- Erian, J. (1994) Endometrial ablation in the treatment of menorrhagia, *British Journal of Obstetrics and Gynaecology*, 101 (Supplement 11), pp.19-22.
- Fraser, I. S. (1994) Menorrhagia - a pragmatic approach to the understanding of causes and the need for investigations, *British Journal of Obstetrics and Gynaecology*, 101 (Supplement 11), pp.3-7.
- Fraser, I.S., Angsuwathana, S., Mahmoud, F. & S. Yezerski (1993) Short and medium term outcomes after rollerball endometrial ablation for menorrhagia, *Medical Journal of Australia*, 158, pp.454-457.
- Fraser, I.S., McCarron, G. & R. Markham (1984) A preliminary study of factors influencing perception of menstrual blood loss volume, *Obstetrics and Gynecology*, 149, pp.788-793.
- Garry, R., Shelley-Jones, D., Mooney, P. & G. Phillips (1995) Six hundred endometrial laser ablations, *Obstetrics and Gynecology*, 85, pp.24-29.
- Garry, R. (1995) Good practice with endometrial ablation, *Obstetrics and Gynecology*, 85, pp.144-151.

Hallberg, L., Högdahl, A.-M., Nilsson, L. & G. Rybo (1966) Menstrual blood loss - a population study, *Acta Obstet. et Gynecol. Scandinav.*, 45, 320-351.

Janssen, C.A.H., Scholtenm P.C. & A.P.M Heintz (1995) A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss, *Obstetrics and Gynecology*, 85, pp.977-982.

Jenkinson, C., Peto, V. & A. Coulter (1994) Measuring change over time: a comparison of results from global single item of health status and the multi-dimensional SF-36 health status survey questionnaire in patients presenting with menorrhagia, *Quality of Life Research*, 3, pp.317-321.

Lalonde, A. (1994) Evaluation of surgical options in menorrhagia, *British Journal of Obstetrics and Gynaecology*, 101 (Supplement 11), pp.8-14.

Lefler, H.T. & C.F. Lefler (1992) Ablation of the endometrium: three-year follow up for perimenstrual symptoms, *Journal of Reproductive Medicine*, 37(2), pp.147-150.

Lewis, B.V. (1994) Guidelines for endometrial ablation, *British Journal of Obstetrics and Gynaecology*, 101, pp.470-473.

Loffer, F. D. (1995) Good practice with endometrial ablation (letter), *Obstetrics and Gynecology*, 86(5).

Magos, A., Baumann, R., Lockwood, G.M. & A.C. Turnbull (1991) Experience with the first 250 endometrial resections for menorrhagia, *Lancet*, 377, pp.1074-1078.

Newton, J., Barnard, G. & W. Collins (1977) A rapid method for measuring menstrual blood loss using automatic extraction, *Contraception*, 16(3), pp.269-282.

Onbargi, L.C., Hayden, R., Valle, R.F. & G.D. Priore (1993) Effects of power and electrical current density variations in an *in vitro* endometrial ablation model, *Obstetrics and Gynecology*, 82, pp.912-918.

Pinion, S.B. et al (1994) Randomised trial of hysterectomy, endometrial laser ablation, and transcervical endometrial resection for dysfunctional uterine bleeding, *British Medical Journal*, 309(6960), pp.979-983.

Ramey, J.W. et al. (1994) The process of carcinogenesis for endometrial adenocarcinoma could be short: development of a malignancy after endometrial ablation, *Obstetrics and Gynecology*, 170, pp.1370-1371.

Ruta, D.A. et al. (1995) Assessment of patients with menorrhagia: how valid is a structured clinical history as a measure of health status? *Quality of Life Research*, 4, pp.33-40.



Scottish Hysteroscopy Audit Group (1995) A Scottish audit of hysteroscopic surgery for menorrhagia: complications and follow up, British Journal of Obstetrics and Gynaecology, 102, pp.249-254.

Shaw, R.W. (1994) Assessment of medical treatments for menorrhagia, British Journal of Obstetrics and Gynaecology, 101 (Supplement 11), pp.15-18.

Sørensen, S.S., Andersen, L.F. & G. Lose (1994) Endometriosis by implantation: a complication of endometrial ablation, Lancet, 343, p.1226.

Sporrong, T., Rybo, G. & L.A. Mattsson (1992) An objective and subjective assessment of uterine blood loss in postmenopausal women on hormone replacement therapy, British Journal of Obstetrics and Gynaecology, 99, pp.399-401.

Sutton, C.J.G. (1994) Thinning the endometrium prior to ablation: is it worthwhile? British Journal of Obstetrics and Gynaecology, 101 (Supplement 10), pp.10-12.

Townsend, D.E. et al. (1993) Post-ablation-tubal sterilization syndrome, Obstetrics and Gynecology, 82, pp.422-424.

Treatment of dysfunctional uterine bleeding (letters) (1995) British Medical Journal, 310(9982), pp.801-804.

Valle, R.F. (1993) Endometrial ablation of dysfunctional uterine bleeding: role of GnRH agonists, International Journal of Gynecology and Obstetrics, 41, pp.3-15.

Velevil, P. et al (1995) Rate of hospitalization for gynecologic disorders among reproductive-age women in the United States, Obstetrics and Gynecology, 86(5), pp.764-769.

Wathen, P.I., Henderson, M.C. & C.A. Witz. (1995) Abnormal uterine bleeding, Medical Clinics of North America, 79(2), pp.329-344.